Nimesil treatment of gouty arthritis

Terapevticheskii Arkhiv

Volumn 75, Issue 5, 2003, Pages 60-64

  Barskova, V G ^a   Yakunina, I A ^a   Nasonova, V A ^a  

^a NONE

Author keywords

Gouty arthritis; Nimesil; Treatment

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; GLUCOSE; GUANOSINE TRIPHOSPHATE; NIMESIL; UNCLASSIFIED DRUG; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; SULFONAMIDE;

ADULT; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; GOUT; HUMAN; HYPEREMIA; MALE; MEASUREMENT; MOVEMENT (PHYSIOLOGY); PAIN; REST; URTICARIA; AGE; AGED; COMPARATIVE STUDY; MIDDLE AGED; QUESTIONNAIRE; TIME;

ADULT; AGE FACTORS; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, GOUTY; CYCLOOXYGENASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; SULFONAMIDES; TIME FACTORS;

EID: 0642308356     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Fam A. G. Managing problem gout. Ann. Acad. Med. Singapore. 1998; 27(1): 93-99.
2. Hollander J. L. Intra-articular hydrocortisone in arthritis and allied conditions. J. Bone Jt Surg. 1953; 35A: 983-990.
3. Hart F. D., Boardman P. L. Indomethacin: A new non-steroid anti-inflammatory agent. Br. Med. J. 1963; 2: 956-970.
4. Norcross B. M. Treatment of connective tissue diseases with a new nonsteroidal compound (indomethacin). Arthr. and Rheum. 1963; 6: 290.
5. Smuth C. J., Percy J. S. Comparison of indomethacin and fenylbutazone in acute gout. Ann. Rheum. Dis. 1973. 32: 351-353.
6. Altman R. D., Honig S., Levin J. M., Lightfoot R. W. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J. Rheumatol. 1988; 15: 1422-1326.
7. Axelrod D., Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin im the treatment of acute gout. Arthr. and Rheum. 1988; 31: 803-805.
8. Lomen P. L., Turner L. F., Lamborn K. R. et al. Flurbiprofen in the treatment of acute gout: a comparison with indomethacin. Am. J. Med. 1986; 80: 134-139.
9. Ruotsi A., Vainio U. Treatment of acute gouty arthritis with proquazone and indomethacin. Scand. J. Rheumatol. 1978; 21: 15-17.
10. Schumacher H. R., Boice J. A., Daikh D. K. et al. Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. Br. Med. J. 2002; 324(7352): 1488-1492.
11. Singh G., Rosen-Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective - 1997. J. Rheumatol, 1998; 51: 8-16.
12. Thompson M., Percy J. S. Further experience with indomethacin in the treatment of rheumatic disorders. Br. Med. J. 1966; 1: 80-83.
13. Wallace S. L., Robinson H., Masi A. T. et al. Pleliminary criteria for the classification of the acute arthritis of the preliminary gout. Arthr. and Rheum. 1977; 20(3): 895-900.
14. Segasothy M., Clin G. I., Sia K. K. et al. Chronic nephrotoxicity of antiinflammatory drugs used in the treatment of arthritis. Br. J. Rheumatol. 1995; 34: 162-165.
15. Henry D., Page J., Whyte I. et al. Comsumption of non-steroidal antiinflammatory drugs and the development of functional renal impairment in elderly subjects: Results of a case control study. Br. J. Clin. Pharmacol. 1997; 44: 85-90.
16. Tarng D. C., Lin H. Y., Shyong M. L. et al. Renal function in gout patients. Am. J. Nephrol. 1995; 15: 31-37.
17. Unsworthy J., Sturman S., Lunec J., Blake D. R. Renal impairment associated with non-steroidal anti-inflammatory drugs. Ann. Rheum. Dis. 1987; 46: 233-236.
18. Sandler D. P., Smith J. C., Weinberg C. R. et al. Analgesic use and chronic renal disease. N. Engl. J. Med. 1989; 320: 1238-1243.
19. Benett W. M., Debroe M. E. Analgesic nephropathy - a preventable renal disease. Ibid. 1269-1271.
20. Perez-Ruiz F., Calabozo M., Herrero-Beites A. M. et al. Improvement of renal function on patients with chronic gout after prover control of hyperuricemia and gouty bouts. Nephron 2000; 86: 287-291.
21. Faires J. S., McCarty D. J. Acute arthritis in man and dog after synovial injection of sodium urate crystals. Lancet 1962; 2: 682.
22. Seegmiller J. E., Howell R. R., Malawista S. E. The inflammatory reaction to sodium urate. J. A. M. A. 1972; 180: 125.
23. Gordon T. P., Terkeltaub R. A., Ginsberg M. H. Gout: Crystal-induced inflammation. In: Gallin J. L., Goldstein I. M., Snyderman R., eds..Inflammation: Basic principles and clinical correlates. New York: Raven; 1988. 775.
24. Terkeltaub R. A., Zachariae C., Santoro D. et al. Monocyte-derived neutrophil chemotactic factor/interleukin-8 is a potential mediator of crystalinduced inflammation. Arthr. and Rheum. 1991: 34: 894.
25. Guerne P. A., Terkeltaub R. A., Zuraw B., Lotz M. Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes. Ibid. 1989; 32: 1443.
26. Di Giovine F. S., Malawista S. E., Thorton E., Duff G. W. Urate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells. J. Clin. Invest. 1991; 78: 1375.
27. Woolfs A. D., Dieppe P. A. Mediators of crystal-induced inflammation in the joint. Br. Med. Bull. 1987; 43: 429.
28. Terkeltaub R. A. Pathogenesis and treatment of crystal-induced inflammation. In: McCarty D. J., Koopman W. J., eds. Arthritis and allied conditions. London: Lea & Febiger; 1993; 1819.
29. Smith W. L., Borgeat P., Fitzpatrick F. A. The eiscosanoids: cycloxygenase, lipoxygenase and epoxygenase pathway. In: Vance D. E., Vance J., eds. Biochemistry of lipids, lipoproteins and membranes. New York: Elsevier; 1991. 297.
30. Vane J. R., Botting R. M. Mechanism of action of anti-inflammatory drugs. Scand. J. Rheumatol. 1996; 102: 9.
31. Hershmann H. R. Prostaglandin syntase 2. Biochim. Biophys. Acta 1996; 1299: 125.
32. Pouliot M., James M. J., McColl S. R. et al. Monosodium urate microcrystals induce cyclooxygenase-2 in human monocytes. Blood 1998; 91(5): 1769-1776.
33. WHO/NCD/NCM/CRA/99.1. Low Back Pain Initiative: 109-113.
34. Koh W. H., Seah A., Chai P. Clinical presentation and disease associations in gout: a hospital-based study of 100 patients in Singapore. Ann. Acad. Med. Singapore 1998; 27: 7-10.
35. Gutman A. B. Views on the pathogenesis and management of primary gout. 1971. J. Bone Jt Surg. 1972; 54A: 357-372.
36. De Lecuw P. W. Nonsteroidal anti-inflammatory drugs and hypertension. The risk and perspective. Drugs 1996; 51(2): 179-187.